Who are Aplidin®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Farydak, Beleodaq, Treanda, Zolinza, Daunorubicin Hydrochloride, Depakene.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aplidin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Aplidin® — Competitive Intelligence Brief

Aplidin® (Aplidin®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase inhibitor. Area: Oncology.

phase 2 Histone deacetylase inhibitor Histone deacetylase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aplidin® (Aplidin®) — PharmaMar. Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aplidin® TARGET	Aplidin®	PharmaMar	phase 2	Histone deacetylase inhibitor	Histone deacetylase
Farydak	PANOBINOSTAT	Secura	marketed	Histone Deacetylase Inhibitor	Histone deacetylase 4	2015-01-01
Beleodaq	belinostat	Acrotech Biopharma	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 1	2014-01-01
Treanda	BENDAMUSTINE	Baxter	marketed	Alkylating Drug	Histone deacetylase 6	2008-01-01
Zolinza	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01
Daunorubicin Hydrochloride	daunorubicin	Meiji Seika Pharma Co., Ltd	marketed	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01
Depakene	valproic acid	Generic (originally Abbott/AbbVie)	marketed	Anti-epileptic Agent [EPC]	Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2	1978-02-28

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase inhibitor class)

Celgene · 1 drug in this class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
Evopoint Biosciences Inc. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
NCIC Clinical Trials Group · 1 drug in this class
PharmaMar · 1 drug in this class
Telik · 1 drug in this class
Tianjin Medical University Cancer Institute and Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aplidin® — Competitive Intelligence Brief. https://druglandscape.com/ci/aplidin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab